BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10516752)

  • 1. Monitoring of minimal residual leukemia in patients with MLL-AF9 positive acute myeloid leukemia by RT-PCR.
    Mitterbauer G; Zimmer C; Fonatsch C; Haas O; Thalhammer-Scherrer R; Schwarzinger I; Kalhs P; Jaeger U; Lechner K; Mannhalter C
    Leukemia; 1999 Oct; 13(10):1519-24. PubMed ID: 10516752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring of minimal residual disease in patients with MLL-AF6-positive acute myeloid leukaemia by reverse transcriptase polymerase chain reaction.
    Mitterbauer G; Zimmer C; Pirc-Danoewinata H; Haas OA; Hojas S; Schwarzinger I; Greinix H; Jäger U; Lechner K; Mannhalter C
    Br J Haematol; 2000 Jun; 109(3):622-8. PubMed ID: 10886213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of complex genomic breakpoint junctions in the t(9;11) MLL-AF9 fusion gene in acute leukemia.
    Super HG; Strissel PL; Sobulo OM; Burian D; Reshmi SC; Roe B; Zeleznik-Le NJ; Diaz MO; Rowley JD
    Genes Chromosomes Cancer; 1997 Oct; 20(2):185-95. PubMed ID: 9331569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective monitoring of minimal residual disease in acute myeloid leukemia with inversion(16) by CBFbeta/MYH11 RT-PCR: implications for a monitoring schedule and for treatment decisions.
    Laczika K; Mitterbauer G; Mitterbauer M; Knöbl P; Schwarzinger I; Greinix HT; Rabitsch W; Fonatsch C; Mannhalter C; Lechner K; Jaeger U
    Leuk Lymphoma; 2001; 42(5):923-31. PubMed ID: 11697647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells.
    Muñoz L; Nomdedéu JF; Villamor N; Guardia R; Colomer D; Ribera JM; Torres JP; Berlanga JJ; Fernández C; Llorente A; Queipo de Llano MP; Sánchez JM; Brunet S; Sierra J;
    Leukemia; 2003 Jan; 17(1):76-82. PubMed ID: 12529663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients.
    Morschhauser F; Cayuela JM; Martini S; Baruchel A; Rousselot P; Socié G; Berthou P; Jouet JP; Straetmans N; Sigaux F; Fenaux P; Preudhomme C
    J Clin Oncol; 2000 Feb; 18(4):788-94. PubMed ID: 10673520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
    Scholl C; Schlenk RF; Eiwen K; Döhner H; Fröhling S; Döhner K;
    Haematologica; 2005 Dec; 90(12):1626-34. PubMed ID: 16330435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a real-time RT-PCR assay for the quantification of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia.
    Scholl C; Breitinger H; Schlenk RF; Döhner H; Fröhling S; Döhner K;
    Genes Chromosomes Cancer; 2003 Nov; 38(3):274-80. PubMed ID: 14506704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic significance of detecting MLL-AF9 fusion gene expression in patients with acute myeloid leukemia by real-time fluorescence quantitative PCR].
    Huang S; Yang H; Gao L; Dou LP; Xu YY; Wang N; Wang LL; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1435-40. PubMed ID: 24370025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation.
    Kusec R; Laczika K; Knöbl P; Friedl J; Greinix H; Kahls P; Linkesch W; Schwarzinger I; Mitterbauer G; Purtscher B
    Leukemia; 1994 May; 8(5):735-9. PubMed ID: 7514242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular disease eradication is a prerequisite for long-term remission in patients with t(8;21) positive acute myeloid leukemia: a single center study.
    Mitterbauer M; Mitterbauer-Hohendanner G; Sperr WR; Kalhs P; Greinix HT; Fonatsch C; Haas OA; Jäger U; Mannhalter C; Lechner K
    Leuk Lymphoma; 2004 May; 45(5):971-7. PubMed ID: 15291357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia.
    Gaiger A; Schmid D; Heinze G; Linnerth B; Greinix H; Kalhs P; Tisljar K; Priglinger S; Laczika K; Mitterbauer M; Novak M; Mitterbauer G; Mannhalter C; Haas OA; Lechner K; Jäger U
    Leukemia; 1998 Dec; 12(12):1886-94. PubMed ID: 9844919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring minimal residual disease in patients with MLL-AF6 fusion transcript-positive acute myeloid leukemia following allogeneic bone marrow transplantation.
    Takatsuki H; Yufu Y; Tachikawa Y; Uike N
    Int J Hematol; 2002 Apr; 75(3):298-301. PubMed ID: 11999359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel AF9 breakpoint in MLL-AF9-positive acute monoblastic leukemia.
    Alonso CN; Longo PL; Gallego MS; Medina A; Felice MS
    Pediatr Blood Cancer; 2008 Apr; 50(4):869-71. PubMed ID: 18000862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical and experimental studies of childhood acute myeloid leukemia with 11q23/MLL rearrangements].
    He YX; Xue YQ; Wang HY; Shao XJ; Pan JL; Xu J; Yang NC; Ji ZH; Huang YP; Hu SY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Dec; 29(6):677-82. PubMed ID: 23225048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disappearance of AML1-MTG8 transcript by reverse transcriptase polymerase chain reaction in a patient in remission of acute myeloid leukemia (M2) after low-dose cytosine arabinoside.
    Sawada H; Serino Y; Wake A; Yamasaki Y; Izumi Y
    Leuk Res; 1998 Sep; 22(9):853-7. PubMed ID: 9716019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia.
    Boeckx N; Willemse MJ; Szczepanski T; van der Velden VH; Langerak AW; Vandekerckhove P; van Dongen JJ
    Leukemia; 2002 Mar; 16(3):368-75. PubMed ID: 11896540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PML/RAR alpha transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission, relapse and after bone marrow transplantation.
    Perego RA; Marenco P; Bianchi C; Cairoli R; Urbano M; Nosari AM; Muti G; Morra E; Del Monte U
    Leukemia; 1996 Feb; 10(2):207-12. PubMed ID: 8637228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel RT-qPCR assay for quantification of the MLL-MLLT3 fusion transcript in acute myeloid leukaemia.
    Abildgaard L; Ommen HB; Lausen B; Hasle H; Nyvold CG
    Eur J Haematol; 2013 Nov; 91(5):394-8. PubMed ID: 23772754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study.
    Laczika K; Novak M; Hilgarth B; Mitterbauer M; Mitterbauer G; Scheidel-Petrovic A; Scholten C; Thalhammer-Scherrer R; Brugger S; Keil F; Schwarzinger I; Haas OA; Lechner K; Jaeger U
    J Clin Oncol; 1998 Apr; 16(4):1519-25. PubMed ID: 9552061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.